Global Dysmenorrhea Treatment Market By Type (Primary dysmenorrhea, Secondary dysmenorrhea); By Treatment (Pain relievers, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Hormonal birth control, Prostaglandin inhibitors, Vitamin supplements, Surgery, Others); By Distribution Channel (Hospitals and Clinics, Retails stores – Online, Offline, Gynaecologists Clinics, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Dysmenorrhea happens to be the medical term for pain that is caused during monthly periods (menstruation) or at the time of the cramps suffered during this period. There are two different types of dysmenorrhea primary and secondary. Primary dysmenorrhea basically happens to be the name for usual cramps that are witnessed during the menstrual cycle, and is recurring but not due to any underlying disease. Normally the pain starts one or two days prior one experiences her first period or at the time when the bleeding commences. One is likely to feel pain that varies from mild to severe especially in the lower abdomen, thighs and back. Pain normally lasts for the period of 12 hrs to 72 hrs, and one might also possess other symptoms like nausea and vomiting, fatigue, along with diarrhoea. Normal menstrual cramps are likely to turn less painful as one gets older and also stop completely if one have a baby. In case one is having painful periods owing to a disorder or due to any sort of infection in her female reproductive organs, it is known as the secondary dysmenorrhea. Pain from this type of dysmenorrhea normally starts from earlier part in the menstrual cycle and lasts longer than normal menstrual cramps. In this case, one won’t experience any kind of nausea, vomiting, fatigue or diarrhoea. The treatment of dysmenorrhea is normally done with the help of over-the-counter pain relievers, like ibuprofen or naproxen sodium at normal doses usually when one expects at the start of their period to stop cramps. The global dysmenorrhea treatment market is growing aggressively due to various factors.
In terms of revenue, the global dysmenorrhea treatment market was valued at US$ 560.9 Mn in 2021 growing at a CAGR of 4.8% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Dysmenorrhea Treatment Market Revenue & Forecast, (US$ Million), 2015 – 2030
Treatment Outlook
Based on the treatment outlook, the global dysmenorrhea treatment market has been segregated into pain relievers, non-steroidal anti-inflammatory drugs (NSAIDS), hormonal birth control, prostaglandin inhibitors, vitamin supplements, surgery and others. In majority of cases over-the-counter pain relievers are used extensively to treat this disorder, though in certain cases, surgery is likely to be needed. On the other hand, the vitamin supplements are being prescribed on an extensive level to keep pain at bay.
Region Outlook
On the basis of the region, the continent of North America will be accounting for majority of revenue generated by the global dysmenorrhea treatment market in the year 2021. According to a report, prevalence of dysmenorrhea in the American women varies is around 16% and 91% in women that suffer from terrible pain in 2%-29% of the women. This is the reason; the country of the United States contributes to most of the revenue minted by the market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global dysmenorrhea treatment market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the key players operating in the global dysmenorrhea treatment market are:
- AbbVie Inc.
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Daewon Pharmaceutical Co., Ltd
- Dr. Reddy’s Laboratories Ltd
- Juniper Pharmaceuticals Inc.
- Nobelpharma Co., Ltd.
- Novartis AG
- PDC Biotech GmbH
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Vantia Ltd
- Other Market Participants
Global Dysmenorrhea Treatment Market:
By Type
- Primary dysmenorrhea
- Secondary dysmenorrhea
By Treatment
- Pain relievers
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Hormonal birth control
- Prostaglandin inhibitors
- Vitamin supplements
- Surgery
- Others
By Distribution Channel
- Hospitals and Clinics
- Retail stores
- Online
- Offline
- Gynecologists clinics
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 - 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Dysmenorrhea Treatment Market
6. Market Synopsis:
Dysmenorrhea Treatment Market
7. Dysmenorrhea Treatment Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Dysmenorrhea Treatment Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Dysmenorrhea Treatment Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Dysmenorrhea Treatment Market
8. Global Dysmenorrhea Treatment Market Analysis and Forecasts, 2022
- 2030
8.1. Overview
8.1.1. Global
Dysmenorrhea Treatment Market Revenue (US$ Mn)
8.2. Global
Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Primary
dysmenorrhea
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2021
8.2.1.3. Market Forecast, 2022 - 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2021
8.2.1.5.1.2. Market
Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2021
8.2.1.5.2.2. Market
Forecast, 2022 - 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2021
8.2.1.5.3.2. Market
Forecast, 2022 - 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2021
8.2.1.5.4.2. Market
Forecast, 2022 - 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2021
8.2.1.5.5.2. Market
Forecast, 2022 - 2030
8.2.2. Secondary
dysmenorrhea
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 - 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Dysmenorrhea Treatment Market Analysis and Forecasts, 2022
- 2030
9.1. Overview
9.2. Global Dysmenorrhea
Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
9.2.1. Pain
Relievers
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Non-Steroidal
Anti-Inflammatory Drugs (NSAIDS)
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.2.3. Hormonal
birth control
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2021
9.2.3.3. Market Forecast, 2022 - 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2021
9.2.3.5.1.2. Market
Forecast, 2022 - 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2021
9.2.3.5.2.2. Market
Forecast, 2022 - 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2021
9.2.3.5.3.2. Market
Forecast, 2022 - 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2021
9.2.3.5.4.2. Market
Forecast, 2022 - 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2021
9.2.3.5.5.2. Market
Forecast, 2022 - 2030
9.2.4. Prostaglandin
inhibitors
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 - 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2021
9.2.4.5.1.2. Market
Forecast, 2022 - 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2021
9.2.4.5.2.2. Market
Forecast, 2022 - 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2021
9.2.4.5.3.2. Market
Forecast, 2022 - 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2021
9.2.4.5.4.2. Market
Forecast, 2022 - 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2021
9.2.4.5.5.2. Market
Forecast, 2022 - 2030
9.2.5. Vitamin
supplements
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 - 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2021
9.2.5.5.1.2. Market
Forecast, 2022 - 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2021
9.2.5.5.2.2. Market
Forecast, 2022 - 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2021
9.2.5.5.3.2. Market
Forecast, 2022 - 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2021
9.2.5.5.4.2. Market
Forecast, 2022 - 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2021
9.2.5.5.5.2. Market
Forecast, 2022 - 2030
9.2.6. Surgery
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2021
9.2.6.3. Market Forecast, 2022 - 2030
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2015 - 2021
9.2.6.5.1.2. Market
Forecast, 2022 - 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2021
9.2.6.5.2.2. Market
Forecast, 2022 - 2030
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2021
9.2.6.5.3.2. Market
Forecast, 2022 - 2030
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2021
9.2.6.5.4.2. Market
Forecast, 2022 - 2030
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2015 - 2021
9.2.6.5.5.2. Market
Forecast, 2022 - 2030
9.2.7. Others
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2021
9.2.7.3. Market Forecast, 2022 - 2030
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market
Estimation, 2015 - 2021
9.2.7.5.1.2. Market
Forecast, 2022 - 2030
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 - 2021
9.2.7.5.2.2. Market
Forecast, 2022 - 2030
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market
Estimation, 2015 - 2021
9.2.7.5.3.2. Market
Forecast, 2022 - 2030
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 - 2021
9.2.7.5.4.2. Market
Forecast, 2022 - 2030
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market
Estimation, 2015 - 2021
9.2.7.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Treatment
10. Global Dysmenorrhea Treatment Market Analysis and Forecasts, 2022
- 2030
10.1. Overview
10.2. Global
Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
10.2.1. Hospitals
and Clinics
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Retail
stores (Definition, Market Estimation and Penetration, 2015 - 2021, Market
Estimation (2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Online, Offline)
10.2.2.1. Online
10.2.2.2. Offline
10.2.3. Gynecologists
clinics
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 - 2030
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2021
10.2.4.3. Market Forecast, 2022 - 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By
Distribution Channel
11. North America Dysmenorrhea Treatment Market Analysis and
Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North
America Dysmenorrhea Treatment Market Revenue (US$ Mn)
11.2. North
America Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Type
11.2.1. Primary
dysmenorrhea
11.2.2. Secondary
dysmenorrhea
11.3. North
America Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment
11.3.1. Pain
Relievers
11.3.2. Non-Steroidal
Anti-Inflammatory Drugs (NSAIDS)
11.3.3. Hormonal
birth control
11.3.4. Prostaglandin
inhibitors
11.3.5. Vitamin
supplements
11.3.6. Surgery
11.3.7. Others
11.4. North
America Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
11.4.1. Hospitals
and Clinics
11.4.2. Retail
stores
11.4.2.1. Online
11.4.2.2. Offline
11.4.3. Gynecologists
clinics
11.4.4. Others
11.5. North
America Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
11.5.1. U.S
11.5.1.1. U.S Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
11.5.1.1.1. Primary dysmenorrhea
11.5.1.1.2. Secondary dysmenorrhea
11.5.1.2. U.S Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
11.5.1.2.1. Pain Relievers
11.5.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
11.5.1.2.3. Hormonal birth control
11.5.1.2.4. Prostaglandin inhibitors
11.5.1.2.5. Vitamin supplements
11.5.1.2.6. Surgery
11.5.1.2.7. Others
11.5.1.3. U.S Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
11.5.1.3.1. Hospitals and Clinics
11.5.1.3.2. Retail stores
11.5.1.3.2.1. Online
11.5.1.3.2.2. Offline
11.5.1.3.3. Gynecologists clinics
11.5.1.3.4. Others
11.5.2. Canada
11.5.2.1. Canada Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
11.5.2.1.1. Primary dysmenorrhea
11.5.2.1.2. Secondary dysmenorrhea
11.5.2.2. Canada Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
11.5.2.2.1. Pain Relievers
11.5.2.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
11.5.2.2.3. Hormonal birth control
11.5.2.2.4. Prostaglandin inhibitors
11.5.2.2.5. Vitamin supplements
11.5.2.2.6. Surgery
11.5.2.2.7. Others
11.5.2.3. Canada Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
11.5.2.3.1. Hospitals and Clinics
11.5.2.3.2. Retail stores
11.5.2.3.2.1. Online
11.5.2.3.2.2. Offline
11.5.2.3.3. Gynecologists clinics
11.5.2.3.4. Others
11.5.3. Mexico
11.5.3.1. Mexico Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
11.5.3.1.1. Primary dysmenorrhea
11.5.3.1.2. Secondary dysmenorrhea
11.5.3.2. Mexico Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment
11.5.3.2.1. Pain Relievers
11.5.3.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
11.5.3.2.3. Hormonal birth control
11.5.3.2.4. Prostaglandin inhibitors
11.5.3.2.5. Vitamin supplements
11.5.3.2.6. Surgery
11.5.3.2.7. Others
11.5.3.3. Mexico Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
11.5.3.3.1. Hospitals and Clinics
11.5.3.3.2. Retail stores
11.5.3.3.2.1. Online
11.5.3.3.2.2. Offline
11.5.3.3.3. Gynecologists clinics
11.5.3.3.4. Others
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Dysmenorrhea Treatment Market Revenue
(US$ Mn) and Forecasts, By Type
11.5.4.1.1. Primary dysmenorrhea
11.5.4.1.2. Secondary dysmenorrhea
11.5.4.2. Rest of North America Dysmenorrhea Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
11.5.4.2.1. Pain Relievers
11.5.4.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
11.5.4.2.3. Hormonal birth control
11.5.4.2.4. Prostaglandin inhibitors
11.5.4.2.5. Vitamin supplements
11.5.4.2.6. Surgery
11.5.4.2.7. Others
11.5.4.3. Rest of North America Dysmenorrhea Treatment Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
11.5.4.3.1. Hospitals and Clinics
11.5.4.3.2. Retail stores
11.5.4.3.2.1. Online
11.5.4.3.2.2. Offline
11.5.4.3.3. Gynecologists clinics
11.5.4.3.4. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By Type
11.6.3. By
Treatment
11.6.4. By
Distribution Channel
12. Europe Dysmenorrhea Treatment Market Analysis and Forecasts, 2022
- 2030
12.1. Overview
12.1.1. Europe
Dysmenorrhea Treatment Market Revenue (US$ Mn)
12.2. Europe
Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Primary
dysmenorrhea
12.2.2. Secondary
dysmenorrhea
12.3. Europe
Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
12.3.1. Pain
Relievers
12.3.2. Non-Steroidal
Anti-Inflammatory Drugs (NSAIDS)
12.3.3. Hormonal
birth control
12.3.4. Prostaglandin
inhibitors
12.3.5. Vitamin
supplements
12.3.6. Surgery
12.3.7. Others
12.4. Europe
Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.4.1. Hospitals
and Clinics
12.4.2. Retail
stores
12.4.2.1. Online
12.4.2.2. Offline
12.4.3. Gynecologists
clinics
12.4.4. Others
12.5. Europe
Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.1.1.1. Primary dysmenorrhea
12.5.1.1.2. Secondary dysmenorrhea
12.5.1.2. France Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.5.1.2.1. Pain Relievers
12.5.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
12.5.1.2.3. Hormonal birth control
12.5.1.2.4. Prostaglandin inhibitors
12.5.1.2.5. Vitamin supplements
12.5.1.2.6. Surgery
12.5.1.2.7. Others
12.5.1.3. France Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.5.1.3.1. Hospitals and Clinics
12.5.1.3.2. Retail stores
12.5.1.3.2.1. Online
12.5.1.3.2.2. Offline
12.5.1.3.3. Gynecologists clinics
12.5.1.3.4. Others
12.5.2. The UK
12.5.2.1. The UK Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.2.1.1. Primary dysmenorrhea
12.5.2.1.2. Secondary dysmenorrhea
12.5.2.2. The UK Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.5.2.2.1. Pain Relievers
12.5.2.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
12.5.2.2.3. Hormonal birth control
12.5.2.2.4. Prostaglandin inhibitors
12.5.2.2.5. Vitamin supplements
12.5.2.2.6. Surgery
12.5.2.2.7. Others
12.5.2.3. The UK Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.5.2.3.1. Hospitals and Clinics
12.5.2.3.2. Retail stores
12.5.2.3.2.1. Online
12.5.2.3.2.2. Offline
12.5.2.3.3. Gynecologists clinics
12.5.2.3.4. Others
12.5.3. Spain
12.5.3.1. Spain Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.3.1.1. Primary dysmenorrhea
12.5.3.1.2. Secondary dysmenorrhea
12.5.3.2. Spain Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment
12.5.3.2.1. Pain Relievers
12.5.3.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
12.5.3.2.3. Hormonal birth control
12.5.3.2.4. Prostaglandin inhibitors
12.5.3.2.5. Vitamin supplements
12.5.3.2.6. Surgery
12.5.3.2.7. Others
12.5.3.3. Spain Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.5.3.3.1. Hospitals and Clinics
12.5.3.3.2. Retail stores
12.5.3.3.2.1. Online
12.5.3.3.2.2. Offline
12.5.3.3.3. Gynecologists clinics
12.5.3.3.4. Others
12.5.4. Germany
12.5.4.1. Germany Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.4.1.1. Primary dysmenorrhea
12.5.4.1.2. Secondary dysmenorrhea
12.5.4.2. Germany Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.5.4.2.1. Pain Relievers
12.5.4.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
12.5.4.2.3. Hormonal birth control
12.5.4.2.4. Prostaglandin inhibitors
12.5.4.2.5. Vitamin supplements
12.5.4.2.6. Surgery
12.5.4.2.7. Others
12.5.4.3. Germany Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
12.5.4.3.1. Hospitals and Clinics
12.5.4.3.2. Retail stores
12.5.4.3.2.1. Online
12.5.4.3.2.2. Offline
12.5.4.3.3. Gynecologists clinics
12.5.4.3.4. Others
12.5.5. Italy
12.5.5.1. Italy Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.5.1.1. Primary dysmenorrhea
12.5.5.1.2. Secondary dysmenorrhea
12.5.5.2. Italy Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.5.5.2.1. Pain Relievers
12.5.5.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
12.5.5.2.3. Hormonal birth control
12.5.5.2.4. Prostaglandin inhibitors
12.5.5.2.5. Vitamin supplements
12.5.5.2.6. Surgery
12.5.5.2.7. Others
12.5.5.3. Italy Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.5.5.3.1. Hospitals and Clinics
12.5.5.3.2. Retail stores
12.5.5.3.2.1. Online
12.5.5.3.2.2. Offline
12.5.5.3.3. Gynecologists clinics
12.5.5.3.4. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Dysmenorrhea Treatment Market Revenue (US$
Mn) and Forecasts, By Type
12.5.6.1.1. Primary dysmenorrhea
12.5.6.1.2. Secondary dysmenorrhea
12.5.6.2. Nordic Countries Dysmenorrhea Treatment Market Revenue (US$
Mn) and Forecasts, By Treatment
12.5.6.2.1. Pain Relievers
12.5.6.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
12.5.6.2.3. Hormonal birth control
12.5.6.2.4. Prostaglandin inhibitors
12.5.6.2.5. Vitamin supplements
12.5.6.2.6. Surgery
12.5.6.2.7. Others
12.5.6.3. Nordic Countries Dysmenorrhea Treatment Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
12.5.6.3.1. Hospitals and Clinics
12.5.6.3.2. Retail stores
12.5.6.3.2.1. Online
12.5.6.3.2.2. Offline
12.5.6.3.3. Gynecologists clinics
12.5.6.3.4. Others
12.5.6.4. Nordic Countries Dysmenorrhea Treatment Market Revenue (US$
Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
12.5.7.1.1. Primary dysmenorrhea
12.5.7.1.2. Secondary dysmenorrhea
12.5.7.2. Benelux Union Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
12.5.7.2.1. Pain Relievers
12.5.7.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
12.5.7.2.3. Hormonal birth control
12.5.7.2.4. Prostaglandin inhibitors
12.5.7.2.5. Vitamin supplements
12.5.7.2.6. Surgery
12.5.7.2.7. Others
12.5.7.3. Benelux Union Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
12.5.7.3.1. Hospitals and Clinics
12.5.7.3.2. Retail stores
12.5.7.3.2.1. Online
12.5.7.3.2.2. Offline
12.5.7.3.3. Gynecologists clinics
12.5.7.3.4. Others
12.5.7.4. Benelux Union Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
12.5.8.1.1. Primary dysmenorrhea
12.5.8.1.2. Secondary dysmenorrhea
12.5.8.2. Rest of Europe Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
12.5.8.2.1. Pain Relievers
12.5.8.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
12.5.8.2.3. Hormonal birth control
12.5.8.2.4. Prostaglandin inhibitors
12.5.8.2.5. Vitamin supplements
12.5.8.2.6. Surgery
12.5.8.2.7. Others
12.5.8.3. Rest of Europe Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
12.5.8.3.1. Hospitals and Clinics
12.5.8.3.2. Retail stores
12.5.8.3.2.1. Online
12.5.8.3.2.2. Offline
12.5.8.3.3. Gynecologists clinics
12.5.8.3.4. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By Type
12.6.3. By
Treatment
12.6.4. By
Distribution Channel
13. Asia Pacific Dysmenorrhea Treatment Market Analysis and
Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia Pacific
Dysmenorrhea Treatment Market Revenue (US$ Mn)
13.2. Asia
Pacific Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Primary
dysmenorrhea
13.2.2. Secondary
dysmenorrhea
13.3. Asia
Pacific Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment
13.3.1. Pain
Relievers
13.3.2. Non-Steroidal
Anti-Inflammatory Drugs (NSAIDS)
13.3.3. Hormonal
birth control
13.3.4. Prostaglandin
inhibitors
13.3.5. Vitamin
supplements
13.3.6. Surgery
13.3.7. Others
13.4. Asia
Pacific Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.4.1. Hospitals
and Clinics
13.4.2. Retail
stores
13.4.2.1. Online
13.4.2.2. Offline
13.4.3. Gynecologists
clinics
13.4.4. Others
13.5. Asia
Pacific Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
13.5.1. China
13.5.1.1. China Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.1.1.1. Primary dysmenorrhea
13.5.1.1.2. Secondary dysmenorrhea
13.5.1.2. China Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.1.2.1. Pain Relievers
13.5.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
13.5.1.2.3. Hormonal birth control
13.5.1.2.4. Prostaglandin inhibitors
13.5.1.2.5. Vitamin supplements
13.5.1.2.6. Surgery
13.5.1.2.7. Others
13.5.1.3. China Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.1.3.1. Hospitals and Clinics
13.5.1.3.2. Retail stores
13.5.1.3.2.1. Online
13.5.1.3.2.2. Offline
13.5.1.3.3. Gynecologists clinics
13.5.1.3.4. Others
13.5.2. Japan
13.5.2.1. Japan Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.2.1.1. Primary dysmenorrhea
13.5.2.1.2. Secondary dysmenorrhea
13.5.2.2. Japan Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.2.2.1. Pain Relievers
13.5.2.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
13.5.2.2.3. Hormonal birth control
13.5.2.2.4. Prostaglandin inhibitors
13.5.2.2.5. Vitamin supplements
13.5.2.2.6. Surgery
13.5.2.2.7. Others
13.5.2.3. Japan Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.2.3.1. Hospitals and Clinics
13.5.2.3.2. Retail stores
13.5.2.3.2.1. Online
13.5.2.3.2.2. Offline
13.5.2.3.3. Gynecologists clinics
13.5.2.3.4. Others
13.5.3. India
13.5.3.1. India Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.3.1.1. Primary dysmenorrhea
13.5.3.1.2. Secondary dysmenorrhea
13.5.3.2. India Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.3.2.1. Pain Relievers
13.5.3.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
13.5.3.2.3. Hormonal birth control
13.5.3.2.4. Prostaglandin inhibitors
13.5.3.2.5. Vitamin supplements
13.5.3.2.6. Surgery
13.5.3.2.7. Others
13.5.3.3. India Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.3.3.1. Hospitals and Clinics
13.5.3.3.2. Retail stores
13.5.3.3.2.1. Online
13.5.3.3.2.2. Offline
13.5.3.3.3. Gynecologists clinics
13.5.3.3.4. Others
13.5.4. New
Zealand
13.5.4.1. New Zealand Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.4.1.1. Primary dysmenorrhea
13.5.4.1.2. Secondary dysmenorrhea
13.5.4.2. New Zealand Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.4.2.1. Pain Relievers
13.5.4.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
13.5.4.2.3. Hormonal birth control
13.5.4.2.4. Prostaglandin inhibitors
13.5.4.2.5. Vitamin supplements
13.5.4.2.6. Surgery
13.5.4.2.7. Others
13.5.4.3. New Zealand Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.4.3.1. Hospitals and Clinics
13.5.4.3.2. Retail stores
13.5.4.3.2.1. Online
13.5.4.3.2.2. Offline
13.5.4.3.3. Gynecologists clinics
13.5.4.3.4. Others
13.5.5. Australia
13.5.5.1. Australia Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.5.1.1. Primary dysmenorrhea
13.5.5.1.2. Secondary dysmenorrhea
13.5.5.2. Australia Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.5.2.1. Pain Relievers
13.5.5.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
13.5.5.2.3. Hormonal birth control
13.5.5.2.4. Prostaglandin inhibitors
13.5.5.2.5. Vitamin supplements
13.5.5.2.6. Surgery
13.5.5.2.7. Others
13.5.5.3. Australia Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.5.3.1. Hospitals and Clinics
13.5.5.3.2. Retail stores
13.5.5.3.2.1. Online
13.5.5.3.2.2. Offline
13.5.5.3.3. Gynecologists clinics
13.5.5.3.4. Others
13.5.6. South
Korea
13.5.6.1. South Korea Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.6.1.1. Primary dysmenorrhea
13.5.6.1.2. Secondary dysmenorrhea
13.5.6.2. South Korea Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.5.6.2.1. Pain Relievers
13.5.6.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
13.5.6.2.3. Hormonal birth control
13.5.6.2.4. Prostaglandin inhibitors
13.5.6.2.5. Vitamin supplements
13.5.6.2.6. Surgery
13.5.6.2.7. Others
13.5.6.3. South Korea Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.5.6.3.1. Hospitals and Clinics
13.5.6.3.2. Retail stores
13.5.6.3.2.1. Online
13.5.6.3.2.2. Offline
13.5.6.3.3. Gynecologists clinics
13.5.6.3.4. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
13.5.7.1.1. Primary dysmenorrhea
13.5.7.1.2. Secondary dysmenorrhea
13.5.7.2. Southeast Asia Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
13.5.7.2.1. Pain Relievers
13.5.7.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
13.5.7.2.3. Hormonal birth control
13.5.7.2.4. Prostaglandin inhibitors
13.5.7.2.5. Vitamin supplements
13.5.7.2.6. Surgery
13.5.7.2.7. Others
13.5.7.3. Southeast Asia Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
13.5.7.3.1. Hospitals and Clinics
13.5.7.3.2. Retail stores
13.5.7.3.2.1. Online
13.5.7.3.2.2. Offline
13.5.7.3.3. Gynecologists clinics
13.5.7.3.4. Others
13.5.7.4. Southeast Asia Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Dysmenorrhea Treatment Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.8.1.1. Primary dysmenorrhea
13.5.8.1.2. Secondary dysmenorrhea
13.5.8.2. Rest of Asia Pacific Dysmenorrhea Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
13.5.8.2.1. Pain Relievers
13.5.8.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
13.5.8.2.3. Hormonal birth control
13.5.8.2.4. Prostaglandin inhibitors
13.5.8.2.5. Vitamin supplements
13.5.8.2.6. Surgery
13.5.8.2.7. Others
13.5.8.3. Rest of Asia Pacific Dysmenorrhea Treatment Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
13.5.8.3.1. Hospitals and Clinics
13.5.8.3.2. Retail stores
13.5.8.3.2.1. Online
13.5.8.3.2.2. Offline
13.5.8.3.3. Gynecologists clinics
13.5.8.3.4. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By Type
13.6.3. By
Treatment
13.6.4. By
Distribution Channel
14. Middle East and Africa Dysmenorrhea Treatment Market Analysis
and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle
East and Africa Dysmenorrhea Treatment Market Revenue (US$ Mn)
14.2. Middle
East and Africa Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts,
By Type
14.2.1. Primary
dysmenorrhea
14.2.2. Secondary
dysmenorrhea
14.3. Middle
East and Africa Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment
14.3.1. Pain
Relievers
14.3.2. Non-Steroidal
Anti-Inflammatory Drugs (NSAIDS)
14.3.3. Hormonal
birth control
14.3.4. Prostaglandin
inhibitors
14.3.5. Vitamin
supplements
14.3.6. Surgery
14.3.7. Others
14.4. Middle
East and Africa Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
14.4.1. Hospitals
and Clinics
14.4.2. Retail
stores
14.4.2.1. Online
14.4.2.2. Offline
14.4.3. Gynecologists
clinics
14.4.4. Others
14.5. Middle
East and Africa Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts,
By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
14.5.1.1.1. Primary dysmenorrhea
14.5.1.1.2. Secondary dysmenorrhea
14.5.1.2. Saudi Arabia Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
14.5.1.2.1. Pain Relievers
14.5.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
14.5.1.2.3. Hormonal birth control
14.5.1.2.4. Prostaglandin inhibitors
14.5.1.2.5. Vitamin supplements
14.5.1.2.6. Surgery
14.5.1.2.7. Others
14.5.1.3. Saudi Arabia Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
14.5.1.3.1. Hospitals and Clinics
14.5.1.3.2. Retail stores
14.5.1.3.2.1. Online
14.5.1.3.2.2. Offline
14.5.1.3.3. Gynecologists clinics
14.5.1.3.4. Others
14.5.2. UAE
14.5.2.1. UAE Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.2.1.1. Primary dysmenorrhea
14.5.2.1.2. Secondary dysmenorrhea
14.5.2.2. UAE Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.5.2.2.1. Pain Relievers
14.5.2.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
14.5.2.2.3. Hormonal birth control
14.5.2.2.4. Prostaglandin inhibitors
14.5.2.2.5. Vitamin supplements
14.5.2.2.6. Surgery
14.5.2.2.7. Others
14.5.2.3. UAE Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.5.2.3.1. Hospitals and Clinics
14.5.2.3.2. Retail stores
14.5.2.3.2.1. Online
14.5.2.3.2.2. Offline
14.5.2.3.3. Gynecologists clinics
14.5.2.3.4. Others
14.5.3. Egypt
14.5.3.1. Egypt Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts,
By Type
14.5.3.1.1. Primary dysmenorrhea
14.5.3.1.2. Secondary dysmenorrhea
14.5.3.2. Egypt Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.5.3.2.1. Pain Relievers
14.5.3.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
14.5.3.2.3. Hormonal birth control
14.5.3.2.4. Prostaglandin inhibitors
14.5.3.2.5. Vitamin supplements
14.5.3.2.6. Surgery
14.5.3.2.7. Others
14.5.3.3. Egypt Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.5.3.3.1. Hospitals and Clinics
14.5.3.3.2. Retail stores
14.5.3.3.2.1. Online
14.5.3.3.2.2. Offline
14.5.3.3.3. Gynecologists clinics
14.5.3.3.4. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.4.1.1. Primary dysmenorrhea
14.5.4.1.2. Secondary dysmenorrhea
14.5.4.2. Kuwait Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.5.4.2.1. Pain Relievers
14.5.4.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
14.5.4.2.3. Hormonal birth control
14.5.4.2.4. Prostaglandin inhibitors
14.5.4.2.5. Vitamin supplements
14.5.4.2.6. Surgery
14.5.4.2.7. Others
14.5.4.3. Kuwait Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.5.4.3.1. Hospitals and Clinics
14.5.4.3.2. Retail stores
14.5.4.3.2.1. Online
14.5.4.3.2.2. Offline
14.5.4.3.3. Gynecologists clinics
14.5.4.3.4. Others
14.5.5. South
Africa
14.5.5.1. South Africa Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
14.5.5.1.1. Primary dysmenorrhea
14.5.5.1.2. Secondary dysmenorrhea
14.5.5.2. South Africa Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
14.5.5.2.1. Pain Relievers
14.5.5.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
14.5.5.2.3. Hormonal birth control
14.5.5.2.4. Prostaglandin inhibitors
14.5.5.2.5. Vitamin supplements
14.5.5.2.6. Surgery
14.5.5.2.7. Others
14.5.5.3. South Africa Dysmenorrhea Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
14.5.5.3.1. Hospitals and Clinics
14.5.5.3.2. Retail stores
14.5.5.3.2.1. Online
14.5.5.3.2.2. Offline
14.5.5.3.3. Gynecologists clinics
14.5.5.3.4. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Dysmenorrhea Treatment Market
Revenue (US$ Mn) and Forecasts, By Type
14.5.6.1.1. Primary dysmenorrhea
14.5.6.1.2. Secondary dysmenorrhea
14.5.6.2. Rest of Middle East & Africa Dysmenorrhea Treatment Market
Revenue (US$ Mn) and Forecasts, By Treatment
14.5.6.2.1. Pain Relievers
14.5.6.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
14.5.6.2.3. Hormonal birth control
14.5.6.2.4. Prostaglandin inhibitors
14.5.6.2.5. Vitamin supplements
14.5.6.2.6. Surgery
14.5.6.2.7. Others
14.5.6.3. Rest of Middle East & Africa Dysmenorrhea Treatment Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.6.3.1. Hospitals and Clinics
14.5.6.3.2. Retail stores
14.5.6.3.2.1. Online
14.5.6.3.2.2. Offline
14.5.6.3.3. Gynecologists clinics
14.5.6.3.4. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By Type
14.6.3. By
Treatment
14.6.4. By Distribution
Channel
15. Latin America Dysmenorrhea Treatment Market Analysis and
Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin
America Dysmenorrhea Treatment Market Revenue (US$ Mn)
15.2. Latin
America Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Primary
dysmenorrhea
15.2.2. Secondary
dysmenorrhea
15.3. Latin
America Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment
15.3.1. Pain
Relievers
15.3.2. Non-Steroidal
Anti-Inflammatory Drugs (NSAIDS)
15.3.3. Hormonal
birth control
15.3.4. Prostaglandin
inhibitors
15.3.5. Vitamin
supplements
15.3.6. Surgery
15.3.7. Others
15.4. Latin
America Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.4.1. Hospitals
and Clinics
15.4.2. Retail
stores
15.4.2.1. Online
15.4.2.2. Offline
15.4.3. Gynecologists
clinics
15.4.4. Others
15.5. Latin
America Dysmenorrhea Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
15.5.1. Brazil
15.5.1.1. Brazil Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
15.5.1.1.1. Primary dysmenorrhea
15.5.1.1.2. Secondary dysmenorrhea
15.5.1.2. Brazil Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.5.1.2.1. Pain Relievers
15.5.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
15.5.1.2.3. Hormonal birth control
15.5.1.2.4. Prostaglandin inhibitors
15.5.1.2.5. Vitamin supplements
15.5.1.2.6. Surgery
15.5.1.2.7. Others
15.5.1.3. Brazil Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.5.1.3.1. Hospitals and Clinics
15.5.1.3.2. Retail stores
15.5.1.3.2.1. Online
15.5.1.3.2.2. Offline
15.5.1.3.3. Gynecologists clinics
15.5.1.3.4. Others
15.5.2. Argentina
15.5.2.1. Argentina Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Type
15.5.2.1.1. Primary dysmenorrhea
15.5.2.1.2. Secondary dysmenorrhea
15.5.2.2. Argentina Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.5.2.2.1. Pain Relievers
15.5.2.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
15.5.2.2.3. Hormonal birth control
15.5.2.2.4. Prostaglandin inhibitors
15.5.2.2.5. Vitamin supplements
15.5.2.2.6. Surgery
15.5.2.2.7. Others
15.5.2.3. Argentina Dysmenorrhea Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.5.2.3.1. Hospitals and Clinics
15.5.2.3.2. Retail stores
15.5.2.3.2.1. Online
15.5.2.3.2.2. Offline
15.5.2.3.3. Gynecologists clinics
15.5.2.3.4. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Dysmenorrhea Treatment Market Revenue
(US$ Mn) and Forecasts, By Type
15.5.3.1.1. Primary dysmenorrhea
15.5.3.1.2. Secondary dysmenorrhea
15.5.3.2. Rest of Latin America Dysmenorrhea Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
15.5.3.2.1. Pain Relievers
15.5.3.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
15.5.3.2.3. Hormonal birth control
15.5.3.2.4. Prostaglandin inhibitors
15.5.3.2.5. Vitamin supplements
15.5.3.2.6. Surgery
15.5.3.2.7. Others
15.5.3.3. Rest of Latin America Dysmenorrhea Treatment Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
15.5.3.3.1. Hospitals and Clinics
15.5.3.3.2. Retail stores
15.5.3.3.2.1. Online
15.5.3.3.2.2. Offline
15.5.3.3.3. Gynecologists clinics
15.5.3.3.4. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By Type
15.6.3. By Treatment
15.6.4. By
Distribution Channel
16. Competitive Benchmarking
16.1. Brand
Benchmarking
16.2. Market
Share Analysis, 2021
16.3. Global
Presence and Growth Strategies
16.3.1. Mergers
and Acquisitions
16.3.2. Product
Launches
16.3.3. Investments
Trends
16.3.4. R&D
Initiatives
17. Player Profiles
17.1. AbbVie
Inc.
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Boehringer Ingelheim Pharma GmbH & Co. KG
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT Analysis
17.2.7. Business
Strategies
17.3. Daewon Pharmaceutical Co., Ltd
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Dr. Reddy’s Laboratories Ltd
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Juniper Pharmaceuticals Inc.
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Nobelpharma Co., Ltd.
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Novartis AG
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. PDC Biotech GmbH
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Pfizer Inc.
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Sun Pharmaceutical Industries Ltd
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Vantia Ltd
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Other
Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.